NDAORALCAPSULEPriority Review
Approved
Nov 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYPRINE (trientine hydrochloride) is an oral copper-chelating agent indicated for Wilson's disease, an autosomal recessive metabolic disorder causing toxic copper accumulation. It binds excess copper to facilitate urinary excretion, serving as an alternative for patients intolerant of d-penicillamine. The drug demonstrated clinical improvement in 83% of treated patients over a mean 48.7-month treatment period.
$0.702MPart D
LOE ApproachingProduct approaching loss of exclusivity with minimal Medicare Part D utilization (34 claims), indicating a niche rare disease market with small commercial team requirements.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SYPRINE offers limited career growth opportunities due to rare disease indication, minimal market presence ($0.702M annual Part D spending), and impending loss of exclusivity. Roles would be concentrated in medical affairs and specialized rare disease commercialization.
Company
Worked on SYPRINE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.